Challenges in Image-Guided Drainage of Infected Pleural Collections: A Review

Ashu S. Bhalla¹  Manisha Jana¹  Priyanka Naranje¹  Swish K. Singh¹  Irshad Banday¹

¹ Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India

Address for correspondence Priyanka Naranje, MD, DNB, MNAMS, Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, Delhi, India (e-mail: priyanka11sh@gmail.com).

Abstract

Infected pleural fluid collections (IPFCs) commonly occur as a part of bacterial, fungal, or tubercular pneumonia or due to involvement of pleura through hematogenous route. Management requires early initiation of therapeutic drugs, as well as complete drainage of the fluid, to relieve patients’ symptoms and prevent pleural fibrosis. Image-guided drainage plays an important role in achieving these goals and improving outcomes. Intrapleural fibrinolytic therapy (IPFT) is also a vital component of the management. The concepts of image-guided drainage procedures, IPFT, and non-expanding lung are discussed in this review.

Introduction

Infected pleural fluid collections (IPFCs) can be the result of various organisms, the most frequent being bacterial or mycobacterial (tubercular), much less frequently fungal, and are rare in viral infections. This article focuses on IPFCs associated with bacterial pneumonia. In other forms of IPFCs caused by organisms, such as tuberculosis/fungi, basic presentation and treatment remain the same but recommendations may vary in terms of time of intervention. IPFCs associated with bacterial pneumonia may develop in the setting of community-acquired pneumonia (CAP), as well in hospital-acquired pneumonia (HAP). Pneumonia can be complicated by parapneumonic effusion, complicated parapneumonic effusion (CPE), or empyema which are defined subsequently. However, there are a significant number of cases of empyema or CPE that do not have an underlying pneumonia. Moreover, their bacteriologic spectra are not always similar. Other possible causes of empyema include hematogenous spread of infection and contiguous spread from subdiaphragmatic pathologies and trauma.¹–⁴

Management of CPE or empyema requires early and complete drainage, not only to relieve the patient’s symptoms but also to prevent long-term complications of pleural fibrosis, resulting in compromised pulmonary function. Notable existing guidelines in terms of management include those of the British Thoracic Society (BTS)⁵ and American Academy for Thoracic Surgeons (AATS).⁶ The purpose of this review is to highlight key concepts and knowledge essential for optimal interventional radiology (IR) management of CPEs and empyema, to improve short- and long-term patient outcomes.

Diagnosis and Terminology

A concept that needs to be understood is that not all infected pleural fluid collections are empyemas. These could also be complicated parapneumonic/synpneumonic effusions. The differences between these two entities are illustrated in – Table 1.⁷–¹⁰ Further, terms which are employed are related to the clinical settings in which the empyema occurs. These are very similar to the settings of the underlying pneumonia. For example, CPE occurs as a complication of...
Table 1 Differences between empyema and complicated parapneumonic effusion

<table>
<thead>
<tr>
<th>Definition</th>
<th>Pitfalls/fallacies&lt;sup&gt;7–10&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emphyema</td>
<td>Pleural collection, containing either: • Pus • Culture/gram stain positive fluid • Glucose &lt;40 mg/dl suggestive of emphyema • However, laboratory results not always foolproof; clinical context should be taken into consideration</td>
</tr>
<tr>
<td>Complicated parapneumonic effusion</td>
<td>Clinical evidence of infection, and pleural fluid collection with the following features: • pH &lt; 7.2 or • Glucose &lt; 60 mg/dl • Laboratory values may be variable • pH may be elevated by urease-producing organisms such as Proteus</td>
</tr>
</tbody>
</table>

Table 2 Quantification of IPFCs on imaging

<table>
<thead>
<tr>
<th>Modality</th>
<th>Technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>USG</td>
<td>The Goecke 2 formula “Estimated volume (EV) ml = (X + LDD) x 70&lt;sup&gt;14&lt;/sup&gt;”</td>
</tr>
<tr>
<td>CT</td>
<td>AP depth at midclavicular line</td>
</tr>
<tr>
<td></td>
<td>Mild: 3 cm Moderate: 3–10 cm Large: &gt;10 cm</td>
</tr>
<tr>
<td>AP quartile</td>
<td>Mild: first quartile (0–25%) Moderate: second (25–50%) Large: third (50–75%) and fourth (75–100%)</td>
</tr>
</tbody>
</table>

Abbreviations: AP, anteroposterior; CT, computed tomography; IPFC, infected pleural fluid collection; LDD, lung to diaphragm distance; USG, ultrasonography.

Quantification of Pleural Fluid Collection

Quantification of pleural fluid guides the decision for drainage. Pleural effusions can be quantified on ultrasound and CT using various methods which are summarized in Table 2. On ultrasound, the Goecke 2 formula measured in erect position of the patient is reported to most closely correlate with actual fluid drained. Ultrasonography (USG) image is obtained keeping probe longitudinally oriented along dorsolateral/posterolateral aspect of chest wall, and cranio-caudal extent (X) and the lung base to middiaphragmatic distance (LDD)/subpulmonary height is measured. Volume of effusion is measured using formula “estimated volume (EV) ml = (X + LDD) x 70<sup>14</sup>” (Fig. 1A-D).

Computed tomography: one method is to measure anteroposterior (AP) depth at the midclavicular line on axial CT image where the maximum fluid is seen and quantify according to Table 2 (Fig. 1E). Another method is to divide hemithorax in a quartile wherein first AP quartile represents 0 to 25% fluid occupying the hemithorax and suggest effusions are small, second AP quartile represents 25 to 50% effusions that are moderate, and third 50 to 75% or fourth 75 to 100% AP-quartile effusions are large (Fig. 1F). CT volumetry software tool may also be used for estimation.

Staging of Infected Pleural Fluid Collection

Empyema is diagnosed on CT when there is a pleural fluid collection with enhancing visceral and parietal pleural layers, giving rise to “split pleura sign.” Classically, IPFC has been divided into three stages; exudative phase, fibrinopurulent stage, and empyema stage. CT findings indicating the stages are shown in Table 3 and Fig. 2. CPE on USG may appear as clear fluid or fluid with fine internal echoes and on CT may show early pleural thickening.

However, the imaging findings may not always correspond to empyema in pleural fluid analysis. The final diagnosis is made by thoracentesis. Sinusoid sign on USG represents the appearance of wavy pattern on M-mode demonstrated when the visceral and parietal pleura are separated by free fluid (Fig. 3). It may be absent when there is a dense or multiseptated collection.
Management of IPFCs has two main modalities: surgery and percutaneous intervention (tube drainage and intrapleural fibrinolytic therapy [IPFT]). Most available literature suggests surgery as the second line management option, after failure of conservative management or tube thoracostomy. Exceptions to this are presence of sepsis or septic shock or a suspected lung abscess. Very few trials analyzed the efficacy of upfront minimally invasive video-assisted thoracic surgery (VATS) in comparison to tube drainage.

This article will describe the interventional management: goals of treatment are two folds, relieving sepsis and preventing long-term complications (e.g., fibrosis and trapped lung).

### Time to Intervene

Timing and nature of surgery is beyond the scope of this article. Interventional management is discussed here. However, not every parapneumonic effusion needs drainage. If the effusion is mild and the patient is responding to antibiotics, it should not be drained. Unlike diagnostic tap, no volume cut-off is available for IPFT.

Parapneumonic effusion has classically been described to evolve through three stages: exudative, fibrinopurulent, and organizing. The time duration of each stage is variable, and delay in thoracentesis may result in increased morbidity. The diagnostic thoracentesis should be performed proactively in

### Table 3 CT findings indicative of various stages of IPFC

<table>
<thead>
<tr>
<th>Stages</th>
<th>Exudative stage</th>
<th>Fibrinopurulent stage</th>
<th>Organizational stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT findings</td>
<td>• Dependent, biconcave free fluid in pleural space</td>
<td>• Parietal pleural thickening is always present</td>
<td>• Smooth grossly thickened pleura</td>
</tr>
<tr>
<td></td>
<td>• Consolidation in ipsilateral lung</td>
<td>• Split pleura sign present</td>
<td>• Residual fluid may be present</td>
</tr>
<tr>
<td></td>
<td>• No or mild pleural enhancement</td>
<td>• Loculations</td>
<td>• Pleural calcification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Biconvex/lenticular shape</td>
<td>• Extrapleural fat proliferation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Internal septations</td>
<td>• Volume loss of hemithorax with rib crowding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Air foci/air-fluid level (hydropneumothorax)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Edema of extrapleural soft tissue</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CT, computed tomography; IPFC, infected pleural fluid collection.
the earliest suspicion of nonresponse to antibiotics (see "Diagnosis and Terminology"). Similarly, a tube thoracostomy should also be performed at an early stage of the disease, so as to avoid subsequent complications.20,21

**Tube Drainage**

While surgical drainage enables one to use larger bore tubes (up to 32–40 Fr), image-guided drainage is typically described to suffer from the drawback of smaller size of the tubes. Though there is no consensus on the size of the optimal chest tube for drainage, for most IPFCs, a small-bore catheter of size 10 to 14 F will be adequate. With the advances in percutaneous drainage tube technology, larger bore tubes, even up to 32 Fr (Thal-Quick, Cook Medical, United States),22 are now available and can be used for thick stubborn collection not responding to small bore catheter drainage. In cases with rib crowding, it is advisable to measure the intercostal space and calculate tube size accordingly. Pigtail catheter is commonly preferred due to the presence of multiple side holes. Malecot catheter is also another preferred self-retaining drainage catheter.

Technique principles of standard trocar and Seldinger’s techniques of tube insertions are similar to all drainage procedures elsewhere in the body. Complete discussion of the techniques is beyond the scope of this review. A few points specific to thoracic drainage are emphasized. Standard site of catheter insertion is along the midaxillary line in fifth or sixth intercostal space and direction of insertion being superior to inferior. However in case of loculated effusions, such universal approach will have to be modified according to site of loculation. Care should be taken that no air is introduced into the pleural space during entire procedure and use of three ways are helpful. After the catheter is placed, it should be connected to an underwater seal drainage bag. USG along with fluoroscopy is a good combination modality for guiding the procedure. CT also can be adapted accordingly, especially in case of rib crowding and when USG visualization is poor.

Outcome of empyema having frank pus vis-a-vis CPE may not be largely different. Whereas it has been demonstrated that frank pus does not essentially imply a tube thoracostomy failure, absence of pus is usually associated with a good outcome of tube thoracostomy.21–26 Larger bore tubes have higher pain scores but offer no additional advantage in terms of prevention of surgical intervention or mortality.

Catheter removal: although literature states, for removal of tube, the output volume to be 200 ml/day in general,27 the decision of tube removal in clinical practice is based on combination of factors such as radiological reduction in size of pleural fluid collection, clinical resolution of sepsis, and fever with no significant drainage output for 48 to 72 hours. Hence, the catheter can be retained even with output < 200 ml/day, as several of these collections do not have large volumes. Reasons for inadequate drainage include thick, viscous collection and presence of loculations. Postinsertion monitoring consists of output monitoring, checking for any tube kink and regular flushing of the tube. Simple saline irrigation has been proven to be useful.28 It has been found superior to tube drainage alone. Thrice daily irrigation with 200 mL of saline for 3 days is recommended.28 Due to improper fixing or accidental misplacement, there may be tube displacement (∼ Fig. 4). Repeat chest X-ray (CXR) can be helpful. In the authors’ experience, a low-dose CT can be used in the follow-up before repositioning of catheters.

**Intrapleural Fibrinolytic Therapy**

While IPFT forms an important component in the management of IPFCs, their use is very variable among institutions. This topic will be discussed under the following headings: Indications, choice of pharmacologic agent, benefits, adverse effects, and cost-effectiveness issues.

**Indications**

The primary indication for IPFT is organizing phase of empyema with loculations and fibrin deposition which may not resolve completely with tube thoracostomy alone; resulting in nonexpansion of underlying lung. IPFT aims to lyse the loculations caused by fibrin deposition.

**Choice of Pharmacologic Agent**

Streptokinase/urokinase are the pharmacologic agents used in the earlier trial (multicenter intrapleural sepsis trial [MIST] 1). In comparison to placebo, they were not found to have any improved outcome (in terms of death, surgical referral or duration of hospital stay). Tissue plasminogen activator (tPA) acts by virtue of its fibrinolytic property. It can either be used alone or in combination with other agents. The viscosity of empyema fluid is caused by extracellular DNA. Deoxyribonuclease (DNase) is another agent which acts by
degrading them. Also, they help destroy bacterial biofilm. DNase is reported to increase the efficacy of streptokinase or tPA. A combination of tPA and DNase was reported to be more effective than any other combinations with respect to a reduction of surgical referral and morbidity.

Frequency and Dosage
Various recommendations exist, ranging from 2 to 100 mg of tPA, for dwell time varying from 30 minutes to 4 hours. MIST2 trial recommends twice daily administration of a dose of 10 mg of tPA and 5 mg of DNase; instilled sequentially with a gap of 2 hours. Individual dwell time for each agent is 1 hour. In case of simultaneous administration of two agents; a dwell time of 2 hours should be allowed. The duration of treatment is also not uniform, and mostly individualized. However, a duration of 3 days is recommended by MIST2 trial; and any prolongation of treatment duration does not lead to improved outcome.

Benefits
Improved outcome of tube drainage in terms of reduced rate of surgical intervention and death (Fig. 5).

Adverse Effects
Intrapleural administration of tPA does not cause systemic bleeding because they do not have significant systemic absorption. However, they can cause local (pleural) hemorrhage, especially at a higher dose. The maximum safe dose is variable according to different studies, ranging from 20 to 100 mg. Intrapleural hemorrhage is mostly treatable with conservative measures and stoppage of IPFT. Anaphylaxis to streptokinase is also a documented adverse effect which can be life threatening.

Cost-Effectiveness Issues
IPFT reduces the rates of surgical referral and, therefore, the surgical cost. However, the additional period of hospital stay and the cost of fibrinolytics should also be taken into consideration. A recent meta-analysis did not show any benefit of IPFT in terms of duration of hospital stay. This is more relevant in resource-constrained countries like India.

The summary of the pharmacologic agents and their dosage is further listed in Table 4.

Important Trials on Intrapleural Fibrinolytic Therapy
The topic of the efficacy of IPFT is a matter of perpetual confusion. Several large studies/trials have taken place in the last few decades, a few of them are being discussed hereinafter.

Multicenter Intrapleural Sepsis Trials 1 and 2
These two large trials originated from the United Kingdom. MIST1 trial was conducted between 1999 and 2002 on 454 patients, with the objective of establishing the efficacy and safety of intrapleural streptokinase in patients of empyema and CPE. This study concluded that intrapleural streptokinase

Table 4 Comparison of pharmacologic agents for IPFT

<table>
<thead>
<tr>
<th>Agent name</th>
<th>Mechanism of action</th>
<th>Dosage</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptokinase/urokinase</td>
<td>Promotes fibrinolysis by activation of plasmin</td>
<td>250,000 units dissolved in 30 mL saline and instilled through thoracostomy tube once/twice daily for six doses</td>
<td>• Anaphylaxis (uncommon, with streptokinase only, not urokinase) • Generalized bleeding tendencies</td>
</tr>
<tr>
<td>tPA</td>
<td>Activation of plasminogen to form plasmin and degrade fibrin</td>
<td>10 mg of t-PA through thoracostomy tube, followed by a dwell time of 1 hour. Twice daily for 3 days</td>
<td>• Local site pain • Erythema/rash • Intrapleural hemorrhage • Hemoptysis</td>
</tr>
<tr>
<td>DNase</td>
<td>Degrades bacterial biofilm and reduces viscosity of pus (it contains extracellular DNA)</td>
<td>5 mg through thoracostomy tube, followed by a dwell time of 1 hour. Twice daily for 3 days</td>
<td>• Local site pain • Erythema/rash • Intrapleural hemorrhage • Hemoptysis</td>
</tr>
</tbody>
</table>

Abbreviations: DNase, deoxyribonuclease; IPFC, infected pleural fluid collection; tPA, tissue plasminogen activator.
did not improve mortality, rate of surgery or length of the hospital stay, and was associated with significant adverse effects.\textsuperscript{24} MIST2 trial, conducted from 2005 to 2008, evaluated the efficacy of other intrapleural fibrinolytic agents (tPA and DNase) on 210 patients (\textsuperscript{Supplementary Table S1}; available in the online version). This trial had four arms (tPA alone, DNase alone, combination, and placebo). The investigators concluded that intrapleural t-PA-DNase therapy improved fluid drainage and reduced the frequency of surgical referral, and hospital stay. Treatment with DNase alone or t-PA alone was ineffective.\textsuperscript{25} Another meta-analysis comparing IPFT with placebo reported that IPFT reduces the need for surgical referral and low risk of overall mortality.\textsuperscript{26} A flowchart summarizing the indications for various intervention steps is depicted in \textsuperscript{Fig. 6}:

**Special Situations**

**Bronchopleural Fistula**

Bronchopleural fistula (BPF) can develop after lung resections (commoner) and as a complication of necrotizing pneumonia (rare). The incidences of BPF after pulmonary resections have reduced with the advent of good antibiotics. The reported incidence of BPF is higher in cases of pneumonectomy rather than lobectomy. Several other factors govern the risk of developing a postoperative BPF.

A necrotizing pneumonia can occasionally give rise to BPF (\textsuperscript{Fig. 7}). Long-term tube thoracostomy is recommended. A word of caution worth mentioning is that in empyema associated with BPF, IPFT is contraindicated. Studies have demonstrated the utility of apposing the serratus anterior muscle in the chest cavity for the closure of fistula during thoracoscopic debridement in children.\textsuperscript{35}

**Unexpandable Lung**

Unexpandable lung is a term used to define the condition when the visceral and parietal pleura do not appose even after adequate pleural fluid drainage. It can occur as a result of empyema, CPE, malignant pleural effusion, uremic effusion, hemothorax, and radiation-induced or pleurodesis-induced pleural damage.

The underlying mechanism of nonexpansion of lung can be as follows:

1. Central obstruction of the subtending bronchus (\textsuperscript{Fig. 8A}).
2. Prolonged atelectasis which leads to inadequate subsequent expansion (\textsuperscript{Fig. 8B}).

It is important to understand the difference between two terminologies used in relation to nonexpansion of the lung, “lung entrapment” and “trapped lung.” Failure of apposition of pleural layers can be seen either during an active pleural inflammatory process (or malignancy) or in healed diseases where there is no active inflammation. The term “lung entrapment” is used when active inflammation is present while “trapped lung” is used in cases of healed infections. (\textsuperscript{Fig. 9})

\textsuperscript{Fig. 10} describes the pathogenesis and clinical manifestations of these two entities. Pleural manometry is useful in differentiating these two entities. Ultrasound demonstrates an absence of normal “sinusoid sign” in both these situations. CT is crucial in identifying the cause of nonexpansion.

The clinical manifestations arise out of the inability of the lung to expand. When a large amount of pleural fluid is drained, and yet the lung cannot expand, it creates a characteristic sharp pain. This pain has been typically described to resolve after injection of air into the pleural space (“therapeutic pneumothorax”). In case of a more pronounced negative intrapleural pressure, small peripheral airways may rupture, leading to pneumothorax (“pneumothorax-ex-vacuo”). This pneumothorax is usually asymptomatic, as it is actually a way to normalize the negative pressure within the pleural cavity. Reexpansion pulmonary edema is also a dreaded complication of excessive pleural fluid drainage in the background of an unexpandable lung.

**Empyema in Children**

Incidence of CPE and empyema in children is lower than in adults. However, these are different from the adult
counterpart, both in terms of epidemiology, as well as management strategies.

First, decision of tube thoracostomy is usually based on clinical (failure to respond to appropriate antibiotic treatment) and imaging parameters. CT is not routinely recommended. A baseline CT may be performed. However, USG is preferred for monitoring. Echogenic contents, debris, loculations, and pleural thickening should call for escalation of management. In follow-up, USG is preferred as ultrasonographic visualization is much better in children owing to thinner chest wall musculature.

Second, the procedure of tube drainage should always be performed under proper sedation (in older children) and general anesthesia (in case of very small children). In case of procedure under sedation in an interventional radiology suite, proper patient monitoring should be ensured.

Third, there is no consensus recommendation regarding the optimal tube size in children. Several large studies have produced conflicting reports. In a large single-center study from the United Kingdom,39 smaller bore tubes were recommended in children. The advantages include superior patient comfort, less pain and reduced hospital stay. The same study has recommended a size of 8.5 Fr for older children,39 and even smaller bore tubes in younger children.

Lastly, several technical nuances are worth noting in pediatric procedures. Single step trocar technique is often preferred over Seldinger’s technique in children.37 The aspiration of pleural fluid should be gradual (maximum: 10 mL/kg) to avoid reexpansion pulmonary edema. In children, adhesive devices are preferred over sutures. Fibrinolytic dosage is also different in children. The recommended dose is 10,000 U urokinase diluted in 10 mL of normal saline in infants and 40,000 U urokinase in 40 mL of normal saline in older children. A dwell time of 4 hours should be followed by an 8-hour drainage at a negative suction of 10 to 20 cm H₂O.

Summary of Guidelines

Several guidelines are available regarding diagnosis, management, and pharmacologic choices in IPFCs. Herein, we shall summarize the salient points from the AATS guidelines (►Table 5).
**Table 5** Summary of recommendations according to AATS guidelines

<table>
<thead>
<tr>
<th>Clinical diagnosis: when to suspect empyema</th>
<th>Recommendations (class I)</th>
<th>Recommendations (class IIa)</th>
<th>Recommendations (class IIb)</th>
<th>Not recommended (class III)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pleural fluid analysis</td>
<td>Presence of pus, or Gram stain positive pleural fluid, or pleural fluid pH &lt; 7.2 should indicate presence of empyema</td>
<td>Pleural fluid LDH &gt; 1,000 IU/L, glucose &lt; 40 mg/dL; or presence of loculations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging evaluation: which study to perform?</td>
<td>CXR and pleural USG to be done routinely; both for diagnostic and for image guided therapeutic procedures</td>
<td>CT should be done in all</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Acute empyema**

<table>
<thead>
<tr>
<th>Antibiotic treatment in acute empyema</th>
<th>Antibiotic should be chosen based on culture reports, if available (LOE C)</th>
<th>Intrapleural antibiotic treatment is not useful (LOE C)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Thoracocentesis without tube placement in acute empyema</td>
<td></td>
<td></td>
<td>Not recommended (LOE C)</td>
<td></td>
</tr>
<tr>
<td>Image guided drain placement in acute empyema</td>
<td>• Helpful in early stages when there are less number of septae (LOE B)</td>
<td>In the presence of thick septae, image guided tube placement can be done in patients not suitable for surgery (LOE C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tube should be regularly flushed to avoid blockage (LOE B)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Follow-up CT and management escalation (if needed) are recommended (LOE C)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 10** Lung entrapment versus trapped lung: pathogenesis and clinical manifestations.
Table 5 (Continued)

<table>
<thead>
<tr>
<th></th>
<th>Recommendations (class I)</th>
<th>Recommendations (class IIa)</th>
<th>Recommendations (class IIb)</th>
<th>Not recommended (class III)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPFT in acute empyema</td>
<td>Should not be routinely used in CPE and early empyema (LOE A)&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical management in acute empyema</td>
<td>VATS should be performed in stage-II acute empyema (LOE B)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Chronic empyema**

**Chronic empyema: tube drainage**

**Chronic empyema: decortication**

**Empyema in children**

May be considered in patients with small chronic empyema/small BPF (if unfit for surgery; LOE C)

Should be done in all patients who can withstand the surgical procedure

Should be treated with small bore tube<sup>b</sup> thoracostomy first (LOE A; with or without IPFT)

Thoracoscopic procedure should be performed in cases of non-response to tube thoracostomy and IPFT (LOE B)

**Abbreviations:** AATS, American Academy for Thoracic Surgeons; BPF, bronchopleural fistula; CAP, community-acquired pneumonia; CPE, complicated parapneumonic effusion; CT, computed tomography; CXR, chest X-ray; HAP, hospital-acquired pneumonia; LDH, lactate dehydrogenase; LOE, level of evidence; USG, ultrasonography; VATS, video-assisted thoracic surgery;

<sup>a</sup>This remains a matter of debate; as several prominent trials (e.g., multicenter intrapleural sepsis trial 2) advocate the use of IPFT to improve outcome and avoid surgery. In practice, it largely depends on multiple factors as follows: (1) institutional protocol; (2) availability of experienced thoracic surgeon for decortication which is a major surgical procedure; (3) availability of appropriate surgical infrastructure, especially in emergency hours; (4) patient suitability for undergoing a major surgical procedure; and (5) experience of the interventional radiology team.

<sup>b</sup>Choosing an optimum tube size in children is also a controversial topic (discussed in detail above).

**Conclusion**

IPFCs, secondary to pyogenic infections, require early complete drainage of the fluid in addition to systemic drugs. Image-guided drainage along with IPFT plays an important role in improving outcomes.

**Supplementary Material**

**Conflict of interest**

There are no financial or nonfinancial conflicts.

**References**

10. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of
13 Lin YC, Chen HJ, Liu YH, Shih CM, Hsu WH, Tu CY. A 30-month experience of thoracic empyema in a tertiary hospital: emphasis on differing bacteriology and outcome between the medical intensive care unit (MICU) and medical ward. South Med J 2008;101(05):484–489